SAN CARLOS, Calif.--(BUSINESS WIRE)--Engage Biologics Inc. (“Engage”), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company (“Lilly”). Engage is developing the Tethosome platform, a novel non-viral DNA delivery system designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosa
Science BusinessWire May 20, 2026